Enabling Social Interaction Through Embodiment in ExCITE

No abstract availableThe emerging demographic trends toward an aging population involve an unflagging research of ways of assisting elderly people to stay independent for as long as possible. This means to be active at home and in the labour market, to prevent social isolation and promote societal inclusion. Both ICT and robotics technologies can contribute to help achieving these goals. This paper introduces the aims of the Ambient Assisted Living project ExCITE whose main objective is to enhance a robotic platform for telepresence with features enabling social interaction from a domestic environment to the outside world. The whole ExCITE project uses a user-centered approach hence it evolves around an intensive evaluation to be performed in situ, on a PanEuropean scale. An existing prototype, called Giraff, is to be deployed to targeted end-users, and refined taking into account outcome of the evaluation. This paper introduces the objectives of ExCITE and offers a description of its initial activities particularly focused on the user evaluation

Towards a Methodology for Longitudinal Evaluation of Social Robotic Telepresence for Elderly

This paper describes a methodology for performing longitudinal evaluations when a social robotic telepresence system is deployed in realistic environments. This work is the core of an Ambient Assisted Living Project called ExCITE, Enabling Social Interaction Through Telepresence. The ExCITE project is geared towards an elderly audience and has as aim to increase social interaction among elderly, their family and healthcare services by using robotic telepresence. The robotic system used in the project is called the Giraff robot and over a three year period, prototypes of this platform are deployed at a number of test-sites in different European countries where user feedback is collected and feedback into the refinement of the prototype. In this paper, we discuss the methodology of ExCITE in particular relation to other methodologies for longitudinal evaluation. The paper also provides a discussion of the possible pitfalls and risks in performing longitudinal studies of this nature particularly as they relate to social robotic telepresence technologies

Towards a methodology for longitudinal evaluation of social robotic telepresence for elderly

This paper describes a methodology for performing longitudinal evaluations when a social robotic telepresence system is deployed in realistic environments. This work is the core of an Ambient Assisted Living Project called ExCITE, Enabling Social Interaction Through Telepresence. The ExCITE project is geared towards an elderly audience and has as aim to increase social interaction among elderly, their family and healthcare services by using robotic telepresence. The robotic system used in the project is called the Giraff robot and over a three year period, prototypes of this platform are deployed at a number of test-sites in different European countries where user feedback is collected and fedback into the refinement of the prototype. In this paper, we discuss the methodology of ExCITE in particular relation to other methodologies for longitudinal evaluation. The paper also provides a discussion of the possible pitfalls and risks in performing longitudinal studies of this nature particularly as they relate to social robotic telepresence technologies

ExCITE Project : A Review of Forty-Two Months of Robotic Telepresence Technology

This article reports on the EU project ExCITE with specific focus on the technical development of the telepresence platform over a period of 42 months. The aim of the project was to assess the robustness and validity of the mobile robotic telepresence (MRP) system Giraff as a means to support elderly people and to foster their social interaction and participation. Embracing the idea of user-centered product refinement, the robot was tested over long periods of time in real homes. As such, the system development was driven by a strong involvement of elderly people and their caregivers but also by technical challenges associated with deploying the robot in real-world contexts. The results of the 42-months’ long evaluation is a system suitable for use in homes rather than a generic system suitable, for example, in office environments.Funding Agency:EU AAL-2009-2-125ExCIT

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

International audienc

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo